This afternoon we watched Sarepta Therapeutics rise 2.0% to a price of $106.89 per share. The mid-cap Pharmaceutical company is now trading -39.05% below its average target price of $175.37. Analysts have set target prices ranging from $139.0 to $221.0 per share for Sarepta Therapeutics, and have given the stock an average rating of buy.
The stock has an average amount of shares sold short at 5.6%, and a short ratio of 3.83. Since 4.25% of the company's shares are owned by insiders, we can infer that there is a degree of alignment between management and shareholder interests. Finally, we also note that a significant number of institutional investors are invested in the stock, with 85.4% of Sarepta Therapeutics's shares being owned by this investor type.
Institutions Invested in Sarepta Therapeutics
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2023-03-31 | Vanguard Group Inc | 9% | 8,112,964 | $867,154,174 |
| 2023-03-31 | Blackrock Inc. | 6% | 5,282,695 | $564,640,866 |
| 2023-03-31 | Janus Henderson Group PLC | 5% | 4,908,204 | $524,613,395 |
| 2023-03-31 | JP Morgan Chase & Company | 4% | 3,702,944 | $395,789,177 |
| 2023-03-31 | Avoro Capital Advisors LLC | 4% | 3,650,000 | $390,130,257 |
| 2023-03-31 | EcoR1 Capital, LLC | 3% | 2,999,453 | $320,596,540 |
| 2023-03-31 | Wellington Management Group, LLP | 3% | 2,933,612 | $313,559,124 |
| 2023-03-31 | FMR, LLC | 3% | 2,644,656 | $282,674,062 |
| 2023-03-31 | Bank Of New York Mellon Corporation | 2% | 1,914,718 | $204,654,637 |
| 2023-03-31 | State Street Corporation | 2% | 1,773,976 | $189,611,428 |
Besides an analyst consensus of strong upside potential, other market factors point to there being positive market sentiment on Sarepta Therapeutics.
